Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibiotic Incentives: Pfizer’s Read Touts Exclusivity Voucher

Executive Summary

Providing a transferable period of patent-life extension in exchange for US FDA approval of a new antibiotic would incentivize ‘the whole ecosystem’ to find new treatments for emerging diseases, CEO Ian Read says.


Related Content

Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Best Of BIO: Policy & Regulatory Updates From BIO 2017
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Trump Promises Changes To 'A Lot Of Rules' At US FDA
‘Wildcard’ Patents: Why A REVAMP-ed Proposal Might Work In 2017
To Congress, From Pharma: Love, Hate And Fresh Ideas For 21st Century Cures
Antibiotics Top List Of New Exclusivity Benefits In Draft Cures Legislation
How To Spur Antibiotic Development? Higher Reimbursement, Govt. Funding Proposed By PCAST


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts